Bisphosphonates are the mainstay of treatment for osteoporosis, but uncertainties exist regarding their long-term use. The identification of patients who will benefit from continuing therapy is of primary clinical importance and a subject of current research. Risk factors for fractures are helping to improve decision making, but unanswered questions remain.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Whitaker, M., Guo, J., Kehoe, T. & Benson, G. Bisphosphonates for osteoporosis—where do we go from here? N. Engl. J. Med. 366, 2048–2051 (2012).
Schwartz, A. V. et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 25, 976–982 (2010).
Black, D. M., Bauer, D. C., Schwartz, A. V., Cummings, S, R & Rosen, C. J. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N. Engl. J. Med. 366, 2051–2053 (2012).
McNabb, B. L. et al. BMD changes and predictors of increased bone loss in postmenopausal women following a 5-year course of alendronate. J. Bone Miner. Res. doi:10.1002/jbmr.1864.
Black, D. M. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296, 2927–2938 (2006).
Khan, S. A. et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12, 1700–1707 (1997).
Papapoulos, S. E. & Cremers, S. C. L. M. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 356, 1075–1076 (2007).
Landman, J. O., Hamdy, N. A. T., Pauwels, E. K. J. & Papapoulos, S. E. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J. Clin. Endocrinol. Metab. 80, 3465–3468 (1995).
Black, D. M. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27, 243–254 (2012).
Eastell, R., Hannon, R. A., Wenderoth, D., Rodriguez-Moreno, J. & Sawicki, A. Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 96, 3367–3373 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. E. Papapoulos declares that he has acted as a consultant for and received speakers' fees from Amgen, Merck, Novartis, Roche/GSK and Warner Chilcott.
Rights and permissions
About this article
Cite this article
Papapoulos, S. Bisphosphonates in osteoporosis—beyond 5 years. Nat Rev Rheumatol 9, 263–264 (2013). https://doi.org/10.1038/nrrheum.2013.57
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.57
